TrialsgrambetaRCTs are beautiful

ADVANCE

2008

Action in Diabetes and Vascular Disease

In 11,140 patients with T2DM at high CV risk, gliclazide-based intensive control to HbA1c ≤6.5 % reduced the composite of microvascular and macrovascular events versus standard care.

Result

Efficacy: Composite microvascular + macrovascularHR 0.90 (CI 0.82-0.98) · P = 0.01

Below 1 favours gliclazide-based intensive control to HbA1c ≤6.5 %, above 1 favours standard care.

Also reported: Driven by −21 % new/worsening nephropathy. No mortality increase, no macrovascular benefit.

Original publication
Subtopic
Intensive vs standard glycaemia
Design
RCT, median 5 yr
Relevance
Important: one of several pillars.
Source
ADVANCE Collaborative Group. N Engl J Med. 2008;358(24):2560-2572.doi 10.1056/NEJMoa0802987

Discussion & critique

Counterweight to ACCORD: intensive control with gliclazide was safe, modestly renoprotective and free of the ACCORD mortality signal.